Subscribe to our newsletter

Deep Dive into the Use of Real-World Registry Data as External Control Arms

CorEvitas is now part of Thermo Fisher Scientific. Read More.

Deep Dive into the Use of Real-World Registry Data as External Control Arms with CorEvitas Vice President, Biostatistics, Heather Litman
While clinical registries are a valued source of longitudinal, real-world data, registries also provide expanded options for research and advancing randomized clinical trials.
Understanding when and how to use registries in these use cases is quite nuanced and mandates a targeted approach and innovative expertise.
In this video, Heather Litman, CorEvitas vice president, biostatistics, provides interviewer Jeanne Linke Northrup with a deep dive into the expanded use of registries as external control arms in clinical trials.
Watch this video and learn more:
  • Challenges faced by biopharma companies conducting clinical trials when studying rare conditions.
  • The purpose of a control population in traditional randomized controlled clinical trials.
  • How hybrid control arms can improve the “strength”of control groups.
  • How prospective registries serve as real-world control populations.
  • How to minimize bias between populations or outcome measures across RCT control groups vs. real-world/hybrid controls.
Watch the video: Click Here